Gurdeep Singh¹*, Sarthak Parikh² and Ujval Choksi³

¹Internal Medicine/Endocrinology, Our Lady of Lourdes Memorial Hospital, Binghamton, NY, USA
²Nova Southeastern University College of Osteopathic Medicine, Monroe, NJ, USA
³Our Lady of Lourdes Memorial Hospital, Binghamton, NY, USA

*Corresponding Author: Gurdeep Singh, Internal Medicine/Endocrinology, Our Lady of Lourdes Memorial Hospital, Binghamton, NY, USA.

Received: March 15, 2022; Published: April 29, 2022

Abstract

Telogen effluvium (TE) is a reversible form of hair loss which is an identified sequela of COVID-19 infection. Generally diagnosed by a hair-pull test or a modified wash test, it can cause a non-scarring shedding of hair for months after the resolution of COVID-19. The pathophysiology of TE secondary to COVID-19 is still being understood. Here, we describe a 45-year-old unvaccinated female who was diagnosed with a severe case of telogen effluvium approximately 3 months after her COVID-19 diagnosis, with hair loss that exceeded 80% of her total hair.

Keywords: Telogen Effluvium; COVID 19; Hair Loss

References

1. Shi Y., et al. “An overview of COVID-19”. Journal of Zhejiang University Science B5 (2020): 343-360.
2. Abrantes TF., et al. “Time of onset and duration of post-COVID-19 acute telogen effluvium”. Journal of the American Academy of Dermatology4 (2021): 975-976.
3. Gruenstein D., et al. “Telogen effluvium caused by COVID-19 in Elmhurst, New York: report of a cohort and review”. DOJ10 (2021).
4. Mieczkowska K., et al. “Telogen effluvium: a sequelae of COVID‐19”. International Journal of Dermatology1 (2021): 122-124.
5. Olds H., et al. “Telogen effluvium associated with COVID‐19 infection”. Dermatologic Therapy2 (2020).
6. Chien Yin GO., et al. “Telogen Effluvium – a review of the science and current obstacles”. Journal of Dermatological Science3 (2021): 156-163.
7. Seleit I., et al. “Vitamin D Receptor Gene Polymorphism In Chronic Telogen Effluvium; A Case-Control Study”. CCID 12 (2019)745-750.
8. Manolis AS., et al. “COVID-19 Infection: Viral Macro- and Micro-Vascular Coagulopathy and Thromboembolism/Prophylactic and Therapeutic Management”. Journal of Cardiovascular Pharmacology and Therapeutics 1 (2021): 12-24.
9. Hussain N., et al. “A systematic review of acute telogen effluvium, a harrowing post-COVID-19 manifestation”. Journal of Medical Virology4 (2022): 1391-1401.
10. Aksoy H., et al. “COVID-19 induced telogen effluvium”. Dermatology Therapy 34.6 (2021): e15175.
11. Trüeb RM. “Telogen Effluvium: Is There a Need for a New Classification?”. Skin Appendage Disorder1-2 (2016): 39-44.
12. Rebora A. “Telogen effluvium: a comprehensive review”. Clinical, Cosmetic and Investigational Dermatology 12 (2019): 583-590.
13. Sharquie KE and Jabbar RI. “COVID-19 infection is a major cause of acute telogen effluvium”. Irish Journal of Medical Science (2021): 1-5.
14. Otsuka Y., et al. “Recovery From Alopecia After COVID-19”. Cureus 1 (2022): e21160.

Citation

Citation: Gurdeep Singh., et al. “A Case of Telogen Effluvium as COVID Sequelae". Acta Scientific Women's Health 4.5 (2022): 66-69.

Copyright

Copyright: © 2022 Gurdeep Singh., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.